MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo Improvements observed across key symptoms, including nausea, early satiety, post-prandial fullness and upper abdominal pain Favorable safety and tolerability profiles Late-breaking oral presentation delivered at Digestive Disease Week

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) — OTC Markets Group (OTCQX: OTCM), operator of regulated markets for more than 12,000 U.S. and international securities, today announced the appointment of JP Chan as Senior Vice President and Regional Head, Asia-Pacific. Chan will lead OTC Markets’ regional team out of Hong

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) — OTC Markets Group (OTCQX: OTCM), operator of regulated markets for more than 12,000 U.S. and international securities, today announced the appointment of JP Chan as Senior Vice President and Regional Head, Asia-Pacific. Chan will lead OTC Markets’ regional team out of Hong